171 related articles for article (PubMed ID: 37341658)
21. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
22. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract][Full Text] [Related]
24. Loss of viral genome with altered immune microenvironment during tumour progression of Epstein-Barr virus-associated gastric carcinoma.
Kondo A; Shinozaki-Ushiku A; Rokutan H; Kunita A; Ikemura M; Yamashita H; Seto Y; Nagae G; Tatsuno K; Aburatani H; Koinuma D; Ushiku T
J Pathol; 2023 Jun; 260(2):124-136. PubMed ID: 36806225
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Jeon HM; Lee JS; Kim SH; Yun KH; Park KH; Jeon MK; Lee YH; Yoon HI; Suh JS; Hur H; Kim KS; Kim S; Kim SH; Kim HS
Oncology; 2020; 98(11):817-826. PubMed ID: 32892196
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma.
Issin G; Sayar İ; Demir F; Bakkaloğlu İG; Gamsizkan M; Yildiz Z; Yilmaz I; Özmen SA; Çağatay DV; Zemheri IE; Demiriz M; Günal A
J Environ Pathol Toxicol Oncol; 2023; 42(4):1-14. PubMed ID: 37522564
[TBL] [Abstract][Full Text] [Related]
27. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
28. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.
Yee EJ; Gilbert D; Kaplan J; van Dyk L; Kim SS; Berg L; Clambey E; Wani S; McCarter MD; Stewart CL
J Surg Res; 2024 Apr; 296():742-750. PubMed ID: 38368775
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.
Chen X; Zhang H; Wang M; Liu H; Hu Y; Lin T; Chen H; Zhao M; Chen T; Li G; Yu J; Zhao L
Front Immunol; 2022; 13():783695. PubMed ID: 35401534
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
[TBL] [Abstract][Full Text] [Related]
31. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
[TBL] [Abstract][Full Text] [Related]
32. Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
Yang N; Wu Y; Jin M; Jia Z; Wang Y; Cao D; Qin L; Wang X; Zheng M; Cao X; Jiang J
PeerJ; 2021; 9():e11481. PubMed ID: 34046266
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type.
Koh J; Nam SK; Roh H; Kim J; Lee BC; Kim JW; Ahn SH; Park DJ; Kim HH; Park KU; Chung JH; Kim WH; Lee HS
Genes Chromosomes Cancer; 2019 Jan; 58(1):12-22. PubMed ID: 30239046
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
Nakano H; Saito M; Nakajima S; Saito K; Nakayama Y; Kase K; Yamada L; Kanke Y; Hanayama H; Onozawa H; Okayama H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Goto A; Kono K
Sci Rep; 2021 Jan; 11(1):1982. PubMed ID: 33479394
[TBL] [Abstract][Full Text] [Related]
35. [Characteristics of PIK3CA gene mutations in Her2-low breast cancer].
Pavlenko IA; Povilaitite PE; Makarevich NS; Kaciyaev VY; Petrov AV
Arkh Patol; 2023; 85(4):5-11. PubMed ID: 37530184
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
37. Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors.
Iwasaki A; Shinozaki-Ushiku A; Kunita A; Yamazawa S; Sato Y; Yamashita H; Fukayama M; Seto Y; Ushiku T
Am J Surg Pathol; 2021 Sep; 45(9):1213-1220. PubMed ID: 34310369
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological characteristics of Epstein-Barr virus and microsatellite instability subtypes of early gastric neoplasms classified by the Japanese and the World Health Organization criteria.
Tanabe H; Mizukami Y; Takei H; Tamamura N; Omura Y; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Yuzawa S; Hasegawa K; Sumi Y; Tanino M; Fujiya M; Okumura T
J Pathol Clin Res; 2021 Jul; 7(4):397-409. PubMed ID: 33750036
[TBL] [Abstract][Full Text] [Related]
39. The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression.
Huang SC; Ng KF; Yeh TS; Cheng CT; Chen MC; Chao YC; Chuang HC; Liu YJ; Chen TC
Histopathology; 2020 Aug; 77(2):250-261. PubMed ID: 32343857
[TBL] [Abstract][Full Text] [Related]
40. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
